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In the United States, the practices and opinions of healthcare providers
regarding eating on dialysis are unknown. The purpose of this study was to
understand healthcare provider opinions and in-center hemodialysis
patient practices regarding eating while at the dialysis center. In June 2011,
over 1200 registered dietitians within a large dialysis organization in the
US were surveyed on current practices and opinions of patient food
consumption during dialysis treatment using an online survey.
1223 of 1665 (73%) dialysis facilities responded to the food consumption
survey.n¼1222 Permitted No Guidelines Not allowed
n (%) n (%) n (%)Eating on dialysis 803 (66%) 67 (5%) 352 (29%)
Drinking on dialysis 907 (75%) 87 (7%) 228 (19%)218 (18%) of the respondents stated that the facility practice for
consuming nutritional supplements (eg., liquid nutritional supplements
and/or protein bars) while on dialysis was different than the policy for
consuming food while on dialysis. Interestingly, 1203 (98%) of the
respondents stated consuming food before or after dialysis was allowed.
The top reasons for facility practices that allowed eating during dialysis
were: prevention of hypoglycemia on dialysis, improved kcal intake on
dialysis days, and the opportunity to provide counseling on food products
currently chosen by the patient. The top reasons for facility practices not
permitting eating during dialysis included: potential adverse events
associated with hypotension, GI symptoms, choking, infection, pest control,
and spills. Further analyses are warranted to determine whether there is a
correlation between allowing patients to eat during dialysis treatment and
an improvement in the nutritional status of the patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.499176
TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS WITH A
SUPPLEMENTED LOW PROTEIN DIET AND A SUPPLEMENTED VERY LOW
PROTEIN DIET
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The primary results of the Modiﬁcation of Diet in Renal Disease were
inconclusive and did confuse a lot of physicians about the dietary approach
to CKD management. The study design was ﬂawed and thus compromised
the results and conclusions. Re-analysis of the MDRD study however
clearly showed the beneﬁts of dietary protein restriction and also more
importantly an additional beneﬁt by ketoanalogue supplementation in
delaying progression of CKD. Despite the obvious beneﬁts of protein
restriction, concern has been raised recently especially patients on very
low dietary protein (very-low-protein diets; VLPDs), which could lead to
deterioration in the nutritional status of CKD patients. To address this
particular issue of whether a sVLPD diet induces malnutrition the present
study has been taken up 132 adult patients with Stage 3 to Stage 5
(Predialysis) were initiated on a protein restricted ketoanalogue
supplemented diet after informed consent and the necessary Institutional
Ethics Committee approvals. Based on their affordability, 92 patients
randomly were assigned to the sLPD group whereby they received 0.6 G/Kg
BW of dietary proteins supplemented by ketoanalogues at a dosage of one
tablet per 10 Kg body weight. 40 patients received 0.3 G/Kg BW
supplemented by ketoanalogues at a dose of one tablet per 5 Kg body
weight. Renologs tablets manufactured by La Renon Healthcare Ltd,
Ahmebabad, India were prescribed as the ketoanalogue supplements.
Renal, Metabolic, Nutritional parameters and Anthropometric analysis
were done in both groups at the start of the study and at the end of
6 months of follow up. The mean blood urea in the SLPD group showed a
decrease from 81.17þ_ 00 mg/dl to 74.45þ_30.75 mg/dl (po 0.05) and in
the SVLPD from 78.35þ_00 mg/dl to 66.50þ_34.50 mg/dl (p40.05) at the
end of six months indicating an improvement in renal function . The serum
creatinine also showed a decrease from 3.52þ_00 mg/dl to 3.30
þ_1.63 mg/dl(p40.05) in the SLPD group and a decrease from
3.74þ_00 mg/dl to 3.55þ_1.67 mg/dl(p40.05) in the SVLPD group though
not statistically signiﬁcant. The eGFR showed improvement from
26.76þ_00 ml/min to 30.75þ_17.31 ml/min (po0.05) at end of sixmonths in the SLPD group and an increase from 23.62þ_00 ml/min to
26.35þ_10.58 ml/min(p40.05) in the SVLPD group. Serum albumin
increased from 3.85þ_00 gm/dl to 4.00þ_0.56 gm/dl (po0.05) in the
SLPD group and an increase from 4.03þ_00 gm/dl to 4.07þ_0.47 gm/dl in
the SVLPD group indicating an improvement in nutrition in SVLPD group
(p40.05) . Blood hemoglobin increased from 11.18þ_2.02 gm/dl to
11.48þ_2.14 gm/dl in the SLPD group and an increase from
11.35þ_0.96 gm/dl to 13.22þ_1.03 gm/dl in the SVLPD group. Combined
analysis of both the study groups together(SLPD þSVLPD) showed a
statistically signiﬁcant decrease in blood urea from 80.32þ_0.0 mg/dl to
73.70þ_31.81 mg/dl(po0.05), decrease in serum creatinine from
3.59þ_0.0 mg/dl to 3.38þ_1.64 mg/dl (040.05) and increase in eGFR from
25.82þ_ 0.0 ml/min to 29.42þ_ 15.67 ml/min(o0.05) at the end of six
months of therapy which was statistically signiﬁcant indicating an
improvement in renal function. The serum albumin increased from
3.91þ_0.0 gm/dl to 4.02þ_0.53 gm/dl (po0.05) indicating a statistically
signiﬁcant improvement in nutrition. The protein restricted ketoanalogue
treated patients in this large series showed signiﬁcant improvement in
their renal function, metabolic status and their extensively investigated
nutritional parameters over a period of 6 months. The key here is to use the
right dosage of the ketoanalogue supplements in addition to ensuring strict
compliance of dietary restrictions. It is strongly recommended that
ketoanalogues be routinely used in the conservative management of CKD.
http://dx.doi.org/10.1016/j.krcp.2012.04.500177
INDOXYL SULFATE UPREGULATES RENAL EXPRESSION OF ICAM-1 VIA
PRODUCTION OF ROS AND ACTIVATION OF NF-jB AND P53 IN
PROXIMAL TUBULAR CELLS
Hidehisa Shimizu, Toshimitsu Niwa
Department of Advanced Medicine for Uremia, Nagoya University Graduate
School of Medicine, Nagoya, Japan.
Intercellular adhesion molecule 1 (ICAM-1) plays an important role in
adhesion of monocytes/macrophages to injured tubulointerstitial tissue.
The present study examined whether indoxyl sulfate, a uremic toxin,
regulates renal expression of ICAM-1. The effect of indoxyl sulfate on
expression of ICAM-1was determined using human proximal tubular cells (HK-
2 cells) and following animals: (1) Dahl salt-resistant normotensive rats (DN),
(2) Dahl salt-resistant normotensive indoxyl sulfate-administered rats (DNþ IS),
(3) Dahl salt-sensitive hypertensive rats (DH), and (4) Dahl salt-sensitive
hypertensive indoxyl sulfate-administered rats (DHþ IS). DNþ IS, DH, and
DHþ IS rats showed signiﬁcantly increased mRNA expression of ICAM-1 in the
kidneys compared with DN rats. DHþ IS rats showed signiﬁcantly increased
mRNA expression of ICAM-1 in the kidneys compared with DH rats. Indoxyl
sulfate upregulated mRNA expression of ICAM-1 in HK-2 cells. Inhibitors of
NADPH oxidase, NF-kB and p53 suppressed indoxyl sulfate-induced mRNA
expression of ICAM-1 in HK-2 cells.
In conclusion, indoxyl sulfate upregulates renal expression of ICAM-1
through production of ROS and activation of NF-kB and p53 in proximal
tubular cells. Thus, accumulation of indoxyl sulfate in chronic kidney disease
might be involved in the pathogenesis of tubulointerstitial injury through
induction of ICAM-1 in the kidneys.
http://dx.doi.org/10.1016/j.krcp.2012.04.501178
ORAL ACTIVE VITAMIN D THERAPY AS A POTENTIAL
CHEMOPREVENTION AGAINST POST-TRANSPLANT MALIGNANCY
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Post-transplant malignancy (PTM) is a limiting factor for both patient
and allograft survival in kidney transplant recipients (KTRs). We
hypothesized that active vitamin D compounds (AVDs) could reduce the
development of PTM in KTRs and evaluated the effects of AVD therapy in a
prospective cohort of ambulatory KTRs in a Japanese single center. We used
a propensity score (PS) of having received AVDs estimated by 25 clinically
relevant factors to adjust for these confounders.
Among 218 participants, the mean age was 49.4 (SD, 12.1) years, 63.3%
were male, the median time since transplantation was 11.2 (interquartile
range [IQR], 5.2–17.1) years, and 42.2% had been treated with AVDs at
